B2M (Beta-2-microglobulin)

Importantly, longer dosing intervals reduced infection rates for all-grade infections (from 6.08 infections per patient-year during weekly dosing to 2.25 infections per patient-year during bimonthly dosing) and for severe infections (from 0.81 infections per patient-year during weekly dosing to 0.1 per patient-year during bimonthly dosing). These results underline the importance of the assessment of annualized infection rates to reflect the true infectious burden in patients who were treated with BCMA-directed BsAbs.

At baseline, all patients were managed with topical corticosteroids (TCS), with 6 (27%) patients requiring oral prednisone (PRD) and 17 (63%) steroid-sparing immunosuppressive therapy (SS-IMT)...Intermediate and posterior segment manifestations are common. Treatment with topical and systemic corticosteroids only may be insufficient to prevent disease relapse, with most patients requiring long-term immunosuppressive therapy.

MCO membranes provide clearance of middle-sized uremic toxins. This effect is most prominent for β2-microglobulin and does not differ between the two MCO dialyzers studied. MCO membranes may cause some albumin loss, and heparin requirements may increase during their use.

Concurrent Helicobacter pylori gastritis was treated with a PPI-free eradication regimen. This case highlights the importance of considering PPI-associated ATIN in unexplained pediatric AKI.

The new criteria were able to identify misclassified patients under the old criteria. The 2025 IMWG/IMS criteria outperform legacy risk classification systems in the identification of patients at high risk for early progression and death despite modern therapy.

Grade 3A FL is characterized by marked clinical and biological heterogeneity. Our findings indicate that Ki-67 expression serves as a valuable prognostic marker that can inform therapeutic decision-making in patients with grade 3A FL. The proposed model integrating Ki-67 and clinical variables enhances PFS prediction and supports individualized treatment strategies for these patients.

P2, N=5, Not yet recruiting, Can-Fite BioPharma

These data demonstrate that CD8+ T cells contribute to tumor control even in the absence of direct antigen presentation by tumor cells. More broadly, our work suggests that strategies to activate the effector functions of inflammatory monocytes may limit tumor growth and overcome acquired resistance to immune checkpoint inhibitors.

This study highlights the aggressive nature of AITL and identifies several readily accessible laboratory parameters as important prognostic factors. The protective effect of PD-1 positivity on survival outcomes warrants further investigation. While CHOP/CHOPE remains the standard treatment, the addition of novel targeted therapies shows promise for improving patient outcomes in this challenging lymphoma subtype.

For primary plasma cell leukemia, we should pay attention to the changes in the abnormal morphology and number of plasma cells. With the help of bone marrow smear, flow cytometry and other tests, we can make a clear diagnosis as early as possible and actively carry out treatment at an early stage.

After R-CHOP-like therapy, EBV+DLBCL patients achieved complete and overall response rates of 55.5% (30/54) and 83.3% (45/54), respectively...EBV+ DLBCL in this Chinese cohort was primarily non-GCB. Elevatedβ2-microglobulin and bone marrow invasion independently predicted inferior PFS, while elevatedβ2-microglobulin and anemia predicted inferior OS.

Additionally, high B2M expression correlated with greater T cell infiltration and improved survival following anti-PD1 therapy. Tumor cell B2M expression was independent of TMB and PD-L1 expression, suggesting that B2M expression could serve as an additional biomarker for anti-PD1 response.